AbbVie has announced the start of construction of a $70-million expansion at the AbbVie Bioresearch Center in Worcester, Massachusetts, which serves as a center of excellence for biologics research and development and manufacturing.  

This expansion is part of the company’s previously announced commitment to invest more than $10 billion of capital in the US to broadly support innovation and expand critical biologics manufacturing capabilities and capacity. 

This investment will further expand AbbVie’s US-based domestic biologics manufacturing capacity to meet increased global demand and support US production of current and future oncology and immunology medicines. It will include construction of additional biologics manufacturing areas and a three-story building housing laboratory, warehouse, and office space. Construction will enable the expedited transfer of select oncology products from Europe to the US. 

Separately, in another US-based manufacturing investment, the company announced in August (August 2025) a $195-million investment in its North Chicago, Illinois, manufacturing site to expand domestic active pharmaceutical ingredient (API) production in the US. The new North Chicago API facility will expand AbbVie’s chemical synthesis capabilities in the US to support domestic production of neuroscience, immunology, and oncology medicines. Construction of the new North Chicago API facility is slated to begin in the fall 2025, with the site projected to be fully operational in 2027. 

Source: AbbVie